非霍奇金淋巴瘤患者外周血CD4^＋CD25^highCD127^low调节性T细胞检测的临床意义

Clinical significance of detection of CD4^＋CD25^highCD127^low regulatory T cells in peripheral blood of NHL patients

目的 观察非霍奇金淋巴瘤（NHL）患者外周血CD4^＋CD25^highCD127^low调节性T细胞（Treg细胞）亚群水平的变化,初步探讨其临床意义.方法 采用流式细胞术检测65例NHL患者及29名健康人外周血中Treg细胞,并进行统计分析.结果 在65例NHL患者的外周血中Treg细胞的比例为（6.72±1.38）%,高于健康对照组（5.65±0.68）%（P〈0.05）;Treg细胞在健康对照组为（5.65±0.68）%,NHL患者Ⅰ～Ⅱ期为（6.08±1.18）%,Ⅲ～Ⅳ期为（6.95±0.85）%,差异有统计学意义（P〈0.05）;Treg细胞在健康对照组为（5.65±0.68）%,弥漫大B细胞淋巴瘤为（5.83±0.95）%,其他亚型淋巴瘤为（7.83±1.76）%,差异有统计学意义（P〈0.05）;Treg细胞在乳酸脱氧酶（LDH）正常患者组为（6.97±1.20）%,增高患者组为（6.54±1.02）%,LDH不同水平与健康对照间差异无统计学意义（P〉0.05）.结论 Treg细胞为免疫抑制细胞,可由肿瘤诱导产生,肿瘤患者外周血中Treg细胞高于健康对照组,且随着患者临床分期的增加,Treg细胞比值升高,Treg细胞比值可以作为临床评估瘤负荷的指标.

Objective To investigate the change of CD4^＋CD25^highCD127^low regulatory T cells （Trcg cells） sub-group level in peripheral blood of non-Hodgkin lymphama （NHL） patients, and to explore its clinical significance. Methods Treg cells levels in peripheral blood of lymphoma patients and normal were detected by flow cytometry, followed by statistical analysis. Results In the 65 cases of NHL patients, Treg cells in peripheral blood were （6.72±1.38） %, higher than that in the normal control group （5.65±0.68） % （P 〈0.05）. Percentage of Treg cells are significantly different between clinical stages and normal： [P 〈0.05, normal control group （5.65±0.88） %, Ⅰ -Ⅱ period （6.08±1.18） %, Ⅲ-Ⅳ period （6.95±0.85） %]. The percentage of Treg cells are also different among pathological types of patients and normal [P 〈0.05, normal control group （5.65± 0.68） %. The percentage of Treg diffuse large B-cell lymphoma （5.83±0.95） % and other subtypes of lymphoma （7.83±1.76） %]were observed. It is not sure that Treg cells percentage among patients with different levels of lactate dehydrogenase and normal are significantly different. [P 〉0.05, normal control group （5.65±0.68） %, patients with normal LDH group （6.97±1.20） %, patients with lactate dehydrogenase （6.54±1.02） %]. Conclusion Treg cells induced by tumor and could inhibit the immune cells, Treg cells percentage in peripheral blood of tumor patients is higher than that the normal control group, and increased with the clinical staging, so the percentage of Treg cells may serve as a clinical indicator to evaluate tumor load.